News & Updates

In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.

Exposure to high levels of fine particulate matter (PM2.5) appears to contribute to an increased risk of oestrogen receptor (ER)-positive breast cancer, as shown in a study.

In the COSMIC-313 trial, the addition of the tyrosine kinase inhibitor (TKI) cabozantinib to the immune checkpoint inhibitor (ICI)-doublet regimen comprising nivolumab and ipilimumab (NIVO/IPI) improved progression-free survival (PFS) in patients with previously untreated, advanced renal-cell carcinoma (RCC) who had intermediate or poor prognostic risk according to the IMDC* category.

Perioperative nivolumab plus platinum-based chemotherapy improves pathological complete response (pCR) rate and survival outcomes vs neoadjuvant platinum-based chemotherapy alone in patients with resectable stage IIIA/B non-small-cell lung cancer (NSCLC), results of the NADIM II trial have shown.

In the phase II VELO trial, third-line (3L) treatment with the anti-EGFR* monoclonal antibody (mAb) panitumumab and standard of care (SoC) improved progression-free survival (PFS) in patients with refractory RAS wild-type metastatic colorectal cancer (WT mCRC).

Epidermal growth factor receptor (EGFR)-mothers against decapentaplegic homologue 7 (SMAD7)-Chimeric antigen receptor (CAR) T-cell therapy against nonsmall-cell lung cancer (NSCLC) is on a par with EGFR-dominant‒negative transforming growth factor (TGFbeta) receptor 2 (DNR)-CAR-T in terms of efficacy and resistance to negative TGFβ regulation, a study has shown.